Facebook
Twitter
LinkedIn
ForwardArchived NCCN Tumor Boards: New Approaches to the Management of Resectable Non-Small Cell Lung Cancer
Chemotherapy-based regimens were previously recommended as the only neoadjuvant and adjuvant options for eligible patients with resectable non-small cell lung cancer (NSCLC). However, in recent years, several new systemic therapy regimens were approved by the FDA as additional neoadjuvant or adjuvant treatment options for eligible patients with resectable NSCLC and included in the NCCN Guidelines® for Non-Small Cell Lung Cancer. Clinicians need to be aware of the updated treatment recommendations to ensure optimal outcomes for patients with early-stage NSCLC.
Target Audience
This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants/associates, pharmacists, and other health care professionals who manage patients with cancer.
Learning Objectives
Following this activity, participants should be able to:
- Identify patients with resectable non-small cell lung cancer (NSCLC) who may be eligible for neoadjuvant or adjuvant systemic therapy.
- Recognize the different types of neoadjuvant and adjuvant systemic therapy regimens available for treating resectable NSCLC.
- Review the adverse events that may occur in patients with resectable NSCLC who receive the new neoadjuvant and adjuvant systemic therapy regimens.
Sandip P. Patel, MD
UC San Diego Moores Cancer Center
Kasey Bamel, DNP, FNP-BC, AOCNP
UC San Diego Moores Cancer Center
Van Hilburn, PharmD, BCOP, MBA
UC San Diego Moores Cancer Center
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty Disclosures
The faculty listed below have no financial relationships with ineligible companies to disclose.
Van Hilburn, MBA, PharmD, BCOP
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Kasey Bamel, DNP, AOCNP, FNP-BC
Regeneron Pharmaceuticals: Product/Speakers Bureau
Sandip P. Patel, MD
Amgen Inc.: Grant/Research Support; Scientific Advisor
AstraZeneca Pharmaceuticals LP: Scientific Advisor
AstraZeneca/MedImmune: Grant/Research Support
Bristol Myers Squibb: Grant/Research Support; Scientific Advisor
Certis Oncology: Scientific Advisor
Eli Lilly and Company: Grant/Research Support; Scientific Advisor
Fate Therapeutics: Grant/Research Support
Genentech, Inc.: Scientific Advisor
Gilead Sciences, Inc. Grant/Research Support
Illumina, Inc.: Scientific Advisor
Iovance Pharmaceuticals: Grant/Research Support
Jazz Pharmaceuticals Inc.: Scientific Advisor
Merck & Co., Inc.: Grant/Research Support; Scientific Advisor
Pfizer Inc.: Grant/Research Support; Scientific Advisor
Rakuten Medical, Inc.: Scientific Advisor
Roche/Genentech: Grant/Research Support
SQZ Biotech, Inc.: Grant/Research Support
Tempus: Scientific Advisor
NCCN Staff Disclosures
None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.
Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-25-055-H01-P
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until May 22, 2026. PAs should only claim credit commensurate with the extent of their participation.
Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1 CE contact hour. Activity Code: S00063372; Approval #: 250001667
Available Credit
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing